873079-69-7

Basic information

• Product Name: AX 048
• Synonyms: AX 048;FMFKQXKYWWJNJS-UHFFFAOYSA-N
• CAS NO: 873079-69-7
• Molecular Formula: C₂₂H₄₁NO₄
• Molecular Weight: 383.56524
• Mol File: 873079-69-7.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AX 048(CAS DataBase Reference)
• NIST Chemistry Reference: AX 048(873079-69-7)
• EPA Substance Registry System: AX 048(873079-69-7)

Safety Data

• Hazardous Substances Data: 873079-69-7(Hazardous Substances Data)

Usage

General Description

AX 048 is a proprietary chemical blend designed for use in the oil and gas industry. It is a non-ionic surfactant and demulsifier that is highly effective in breaking emulsions, separating water from crude oil, and reducing the viscosity of heavy oils. This chemical agent is also used as a corrosion inhibitor and scale inhibitor for oil production equipment, helping to extend the lifespan and efficiency of the infrastructure. AX 048 is versatile and can be used in various applications, including offshore platforms, pipelines, and well maintenance operations, making it an essential component in the extraction and processing of oil and gas.

Upstream product

• 5959-36-4 ethyl 4-aminobutyrate 
• 764-67-0 2-hydroxypalmitic acid 

Downstream Products

• 888734-43-8 4-(2-hydroxy-5-phenyl-pentanoylamino)butyric acid methyl ester 

Relevant articles and documents

Systemic and intrathecal effects of a novel series of phospholipase A 2 inhibitors on hyperalgesia and spinal prostaglandin E2 release

Phospholipase A2 (PLA2) forms are expressed in spinal cord, and inhibiting spinal PLA2 induces a potent antihyperalgesia. Here, we examined the antihyperalgesic effects after systemic and i.t. delivery of four compounds constructed with a common motif consisting of a 2-oxoamide with a hydrocarbon tail and a four-carbon tether. These molecules were characterized for their ability to block group IVA calcium-dependent PLA 2 (cPLA2) and group VIA calcium-independent PLA 2 (iPLA2) in inhibition assays using human recombinant enzyme. The rank ordering of potency in blocking group IVA cPLA2 was AX048 (ethyl 4-[(2-oxohexadecanoyl)amino]butanoate), AX006 (4-[(2- oxohexadecanoyl)amino]butanoic acid), and AX057 (tert-butyl-4-[(2- oxohexadecanoyl)amino]butanoate) > AX010 (methyl 4-[(2-oxohexadecanoyl)amino] butanoate) and for inhibiting group VIA iPLA2 was AX048, AX057 > AX006, and AX010. No agent altered recombinant cyclooxygenase activity. In vivo, i.t. (30 μg) and systemic (0.2-3 mg/kg i.p.) AX048 blocked carrageenan hyperalgesia and after systemic delivery in a model of spinally mediated hyperalgesia induced by i.t. substance P (SP). The other agents were without activity. In rats prepared with lumbar i.t. loop dialysis catheters, SP evoked spinal prostaglandin E2 (PGE2) release. AX048 alone inhibited PGE2 release. Intrathecal SR141617, a cannabinoid CB1 inhibitor at doses that blocked the effects of i.t. anandamide had no effect upon i.t. AX048. These results suggest that AX048 is the first systemically bioavailable compound with a significant affinity for group IVA cPLA 2, which produces a potent antihyperalgesia. The other agents, although demonstrating enzymatic activity in cell-free assays, appear unable to gain access to the intracellular PLA2 toward which their action is targeted. Copyright